×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:OGI

OrganiGram (OGI) Stock Forecast, Price & News

$1.16
-0.05 (-4.13%)
(As of 05/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.13
$1.20
50-Day Range
$1.14
$1.81
52-Week Range
$1.10
$3.52
Volume
4.70 million shs
Average Volume
5.51 million shs
Market Capitalization
$363.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.36
30 days | 90 days | 365 days | Advanced Chart
Receive OGI News and Ratings via Email

Sign-up to receive the latest news and ratings for OrganiGram and its competitors with MarketBeat's FREE daily newsletter.

OrganiGram logo

About OrganiGram

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OGI
Fax
N/A
Employees
841
Year Founded
N/A

Sales & Book Value

Annual Sales
$62.43 million
Book Value
$1.26 per share

Profitability

Net Income
$-103.09 million
Pretax Margin
-34.16%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$363.90 million
Optionable
Not Optionable

Company Calendar

Last Earnings
4/12/2022
Today
5/28/2022
Next Earnings (Estimated)
7/12/2022
Fiscal Year End
8/31/2022

MarketRank

Overall MarketRank

1.87 out of 5 stars

Medical Sector

728th out of 1,424 stocks

Pharmaceutical Preparations Industry

346th out of 681 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -













OrganiGram (NASDAQ:OGI) Frequently Asked Questions

Is OrganiGram a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OrganiGram stock.
View analyst ratings for OrganiGram
or view top-rated stocks.

When is OrganiGram's next earnings date?

OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022.
View our earnings forecast for OrganiGram
.

How were OrganiGram's earnings last quarter?

OrganiGram Holdings Inc. (NASDAQ:OGI) issued its earnings results on Tuesday, April, 12th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The company earned $25.04 million during the quarter, compared to analysts' expectations of $24.28 million. OrganiGram had a negative net margin of 32.87% and a negative trailing twelve-month return on equity of 12.28%. During the same period last year, the business earned ($0.09) earnings per share.
View OrganiGram's earnings history
.

What price target have analysts set for OGI?

7 brokerages have issued 12-month price targets for OrganiGram's shares. Their forecasts range from $2.25 to $5.30. On average, they expect OrganiGram's share price to reach $3.43 in the next year. This suggests a possible upside of 195.3% from the stock's current price.
View analysts' price targets for OrganiGram
or view top-rated stocks among Wall Street analysts.

Who are OrganiGram's key executives?
OrganiGram's management team includes the following people:
  • Mr. Derrick W. West CPA, CPA, (CA), Chief Financial Officer (Age 55, Pay $241.72k)
  • Ms. Helen Martin, Chief Legal Officer & Corp. Sec. (Age 44, Pay $226.39k)
  • Mr. Gregory Engel, Special Advisor (Age 57, Pay $452.87k)
  • Mr. Timothy Emberg, Chief Revenue Officer
  • Mr. Paolo De Luca C.A., C.F.A, Chief Strategy Officer (Age 49, Pay $238.52k)
  • Ms. Beena G. Goldenberg, CEO & Director (Age 59)
  • Ms. Nathalie Batten, VP of Operations
  • Amy Schwalm, VP of Investor Relations
  • Ms. Megan Amber McCrae, Sr. VP of Marketing & Communications
  • Tina Shannon, VP of HR
What other stocks do shareholders of OrganiGram own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include KushCo (KSHB), (CGC), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

What is OrganiGram's stock symbol?

OrganiGram trades on the NASDAQ under the ticker symbol "OGI."

Who are OrganiGram's major shareholders?

OrganiGram's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.43%), Bank of Montreal Can (0.73%), Goldman Sachs Group Inc. (0.28%), Connor Clark & Lunn Investment Management Ltd. (0.20%), Swiss National Bank (0.19%) and Vontobel Holding Ltd. (0.17%).

Which major investors are selling OrganiGram stock?

OGI stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Connor Clark & Lunn Investment Management Ltd., Mirae Asset Global Investments Co. Ltd., UBS Group AG, Cutler Group LP, and SIG North Trading ULC.

Which major investors are buying OrganiGram stock?

OGI stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Vanguard Group Inc., Cibc World Market Inc., Mackenzie Financial Corp, Swiss National Bank, Flow Traders U.S. LLC, and Group One Trading L.P..

How do I buy shares of OrganiGram?

Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OrganiGram's stock price today?

One share of OGI stock can currently be purchased for approximately $1.16.

How much money does OrganiGram make?

OrganiGram has a market capitalization of $363.90 million and generates $62.43 million in revenue each year. The company earns $-103.09 million in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does OrganiGram have?

OrganiGram employs 841 workers across the globe.

What is OrganiGram's official website?

The official website for OrganiGram is www.organigram.ca.

How can I contact OrganiGram?

OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at (844) 644-4726.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.